anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this systematic review, we synthesize the literature investigating the effect of experimentally induced pain in the cervical, shoulder, or orofacial regions on cervical neuromuscular and kinematic features. Databases were searched up to November 1, 2023. A total of 29 studies using hypertonic saline injection (n = 27) or glutamate injection (n = 2) as experimental pain models were included. Meta-analyses revealed reduced upper trapezius activation during shoulder flexion/abduction when pain was induced in the upper trapezius (standardized mean difference: -.90, 95% confidence interval: [-1.29; -.51]), splenius capitis (-1.03 [-1.44; -.63]), and supraspinatus (-.63 [-1.25; -.01]), but not in the subacromial space (.22 [-.16; .60]). Furthermore, experimentally induced pain caused a caudal redistribution of activation within the upper trapezius (.96 [.58; 1.34]) but did not change the mediolateral distribution (.11 [-.22; .42]). None of these adaptations persisted after pain resolution. Low-quality evidence supported the absence of an effect of experimental pain on upper trapezius muscle activation during manual dexterity and cervical flexion/extension tasks, as well as on cervical flexor and extensor muscle activation during cervical and jaw tasks. Inconsistent and limited evidence, attributed to the large heterogeneity of task and outcomes, precluded drawing meaningful conclusions about the effects of experimentally induced pain in the cervical region on cervical kinematics. Overall, cervical muscle activation tended to decrease in response to experimentally induced pain, and the decrease of muscle activation depended on the location of the painful stimulus. These adaptations are only partially representative of muscle activation patterns observed in clinical populations. PERSPECTIVE: This systematic review and meta-analysis revealed a reduced or unchanged muscle activation during experimental pain in the cervical, shoulder, or orofacial regions, depending on the task and location of nociceptive stimulation. There was inconsistent evidence on cervical kinematics. These findings enhance our understanding of neuromuscular adaptations to acute experimental pain.
Abstract: Objective: To compare the analgesic effect of sufentanil and ibuprofen and the incidence of vomiting, and to choose better postoperative analgesic drugs for motion sickness patients. Methods: Sixty-eight female patients aged between 18 and 60 years with motion sickness were selected for gynecologic endoscopic surgery under general anesthesia. Sixty-eight female patients were randomly divided into two groups, Group B (ibuprofen group) and Group S (sufentanil group), using a random number table method. The initial plasma target concentration of propofol was set at 4ug/ml and adjusted using the titration method. Once the patient lost consciousness, the target concentration of remifentanil was set at 4ng/ml and rocuronium at 0.6mg/kg, followed by endotracheal intubation three minutes later. During the operation, the plasma target concentration of propofol was maintained at 5ug/ml and remifentanil at 4ng/ml, with adjustments made based on stress reaction levels. General anesthesia was sustained through continuous administration of rocuronium at doses of 5 µg/kg/min. In Group B (ibuprofen group), intravenous administration of ibuprofen (0.8g) took place within half an hour before the end of surgery; in Group S (sufentanil group), intravenous injection of sufentanil (0.2ug/kg) occurred half an hour before completion of the operation, along with intravenous injection of dexamethasone (5mg) five minutes prior to anesthesia induction to prevent postoperative nausea and vomiting in both groups. The following data were collected: duration of operation, pneumoperitoneum time, extubation time, respiratory recovery time; Incidence of postoperative nausea and vomiting at different time intervals: Postanesthesia care unit residence period (T1), 0-3h after extubation (T2), 3-6h after extubation (T3), 6-12h after extubation (T4), 12-24h after extubation (T5); Visual analogue pain score : Postanesthesia care unit residence period (T1), 0-3h after extubation (T2), 3-6h after extubation (T3), 6-12h after extubation (T4), 12-24h after extubation (T5); Frequency of use of analgesics and antiemetic drugs; Incidence of adverse reactions within 24 hours after surgery; Postoperative satisfaction.
What is the relationship between experiencing individual body parts and the whole body as one's own? We theorised that body part ownership is driven primarily by the perceptual binding of visual and somatosensory signals from specific body parts, whereas full-body ownership depends on a more global binding process based on multisensory information from several body segments. To examine this hypothesis, we used a bodily illusion and asked participants to rate illusory changes in ownership over five different parts of a mannequin's body and the mannequin as a whole, while we manipulated the synchrony or asynchrony of visual and tactile stimuli delivered to three different body parts. We found that body part ownership was driven primarily by local visuotactile synchrony and could be experienced relatively independently of full-body ownership. Full-body ownership depended on the number of synchronously stimulated parts in a nonlinear manner, with the strongest full-body ownership illusion occurring when all parts received synchronous stimulation. Additionally, full-body ownership influenced body part ownership for nonstimulated body parts, and skin conductance responses provided physiological evidence supporting an interaction between body part and full-body ownership. We conclude that body part and full-body ownership correspond to different processes and propose a hierarchical probabilistic model to explain the relationship between part and whole in the context of multisensory awareness of one's own body.
BACKGROUND: Remnant cholesterol (RC) has been known as an important factor for the assessment of the metabolic syndrome (Mets) risk. However, the correlation between RC and hyperuricemia (HUA) in type 2 diabetes mellitus (T2DM) remains unclear. This study aims to explore the correlation between RC and HUA in patients with T2DM.
METHODS: A total of 2956 patients with T2DM admitted to the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University from 2020 to 2022 were included. The correlation between RC and HUA was evaluated with Spearman's correlation, multiple logistic regression, subgroup analyses, receiver operating characteristic (ROC) curves analyses and generalized smooth curve fitting. Total cholesterol (TC) < 5.18mmol/L was defined as normal TC.
RESULTS: RC was correlated with uric acid in patients with T2DM (Spearman's correlation coefficient = 0.279, P < 0.001). According to the multiple logistic regression analyses, there was an independent positive correlation between RC and HUA (OR = 1.63, 95%CI = 1.40, 1.90). In addition, a non-linear correlation between RC and HUA was identified. The area under the ROC curve (AUC) of RC (0.658, 95%CI = 0.635, 0.681) was the largest compared with those of low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and TC. Subgroup analyses showed a more significant positive correlation among females or normal TC groups.
CONCLUSION: Elevated RC is correlated with HUA in patients with T2DM significantly and positively. RC is better in its predictability for HUA than that of conventional lipid indexes.
A cell-growing system may include a cell-growing container, a pump for controlling the pressure of the chamber of the container, a filter for maintaining the chamber sterilized, a flow control regulator for controlling the substance supplied to the cell-growing container. The cell-growing container may include an internal structure that takes the form of a reticulated structure to increase the surface area for growing cells. The cell-growing system may be used to perform cycles of cell expansion and harvest. The cell-growing system may be maintained as a closed and sterilized system through the cycles. In harvesting, a first subset of the cells can be disassociated from the cell culture while a second subset remains. The disassociated cells may be discharged to a collection container while maintaining the system closed to an external environment. The remaining cells may be used as seeds to proliferate more cells in the next cycle.
The invention discloses Chinese wolfberry yellow wine and a preparation method thereof. The yellow wine has the functions of softening blood vessels and improving heart blood circulation. Chinese wolfberry serves as a wine making raw material, has multiple effects of reducing blood pressure, resisting cancers and the like and is a traditional Chinese medicine which is beneficial to the human body, so that the yellow wine is pure in taste and rich in nutrition. Compared with the prior art, the Chinese wolfberry yellow wine has the beneficial effects that the Chinese wolfberry yellow wine contains Chinese wolfberry powder and ginger powder and has the effects of expanding coronary artery and improving heart blood circulation. In addition, the Chinese wolfberry serving as the raw material is added into the yellow wine, so that the prepared Chinese wolfberry yellow wine is mellow in taste, the taste of the traditional Chinese medicine is canceled, the nutritional components are enriched, and the yellow wine is suitable for all kinds of consumer groups. Moreover, the preparation process is simple, and the preparation method can be performed on the conventional factory equipment, is low in equipment investment and realizes batch production.
1344265 An anti-hypertensive extract from Anacardium occidentale h ALBERT ROLLAND SA 16 July 1972 [16 July 1970] 34608/70 Heading A5B An extract having antihypertensive properties is obtained by (a) subjecting the ground bark of Anacardium occidentale h. (cashew) to at least one extraction with petroleum ether, (b) after removing the petroleum ether, subjecting the insoluble residue which is left to at least one extraction with diethyl ether, (c) after removing the diethyl ether, subjecting the insoluble residue which remains to at least one extraction with ethanol, methanol, a mixture thereof, or a mixture of either or both with water, (d) after removing the insoluble residue and by concentrating the soluble fraction according to (c) in vacuo at a temperature below 60C, to produce a dry extract, dissolving the dry extract in water, and collecting the anti-hypertensive principle by precipitation with an alkaloid, e.g. caffeine or hide powder, each of the extractions according to (a), (b) and (c) being carried out for at least 3 hours in the absence of light and at a temperature of 0 to 15C. The solvent used in stage (c) may be a water-ethanol or water methanol mixture. The extract obtained may be further purified by precipitation from a methanol solution. The active material may be incorporated into therapeutic compositions, e.g. powders, tablets, dispersible granules, capsules, catchets and suppositories.
The invention provides a Chinese medicinal composition for regulating blood sugar and a preparation method thereof. The composition can be prepared into health-care foods or medicaments, and is mainly suitable for people with high blood sugar and diabetes. The active component consists of at least the following six raw material medicaments: fiveleaf gynostemma herb, hawthorn fruit, yam, dark plum fruit, mulberry fruit and mulberry leaves. The composition has the effects of mainly supplementing vital energy and nourishing yin, invigorating spleen and activating thin fluid, and auxiliarily clearing away heat, eliminating damp and invigorating blood circulation to ensure that the spleen diseases are treated parallelly. The composition not only regulates the symptom of local yin deficiency and dryness heat, in particular foundation of spleen weakness, and ensures that the essence of foods can be absorbed by internal organs of the body to nourish all the limbs and bones, saliva is generated by self, strength is strengthened by self, and the recovery of patients with dispersion-thirst disease (diabetes) is promoted. Animal experiments prove that the Chinese medicinal composition can reduce the value of blood sugar of a rat with the diabetes, improve the carbohydrate tolerance of the rat with the diabetes caused by tetraoxypyrimidine, and has no obvious influence on the blood sugar of a normal mouse.
Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
The objective of the present invention is to allow a hydrogen gas which has a gas mixture concentration of over 4% to be breathed in safely, and to reduce the amount of use of hydrogen gas, which is dangerous, and increase utilization efficiency of the hydrogen gas. The objective of the present invention is also to impart an auxiliary role to a device in the treatment of patients suffering from viral or bacterial pneumonia using hydrogen gas. A hydrogen gas mixture breathing device and a related system employ an intrinsically safe structure and a safety system which prevent occurrence of explosions. A detonation flame arrester, etc. are installed where necessary to provide against electrostatic explosions, etc., and to protect a user's lung function from explosion flames. In addition, a device for supplying aerosol in which a hydroxyl radical is dissolved is also installed, and operating time and volume are appropriately adjusted under the supervision of a professional. Depending on the circumstances, the content of the aerosol is changed to microdroplets that comprise a bivalent iron ion or monovalent copper ion. Suction of a hydrogen-rich gas mixture and suction of the aerosol take place alternatively according to a program and not simultaneously.
Tryptophan is an essential amino acid and must be obtained from the diet. In addition to its essential role in protein synthesis, tryptophan has diverse and complex physiological functions via various metabolic pathways. Two primary metabolic pathways include the kynurenine and serotonin pathways. Tryptophan is the only precursor for both the kynurenine and serotonin pathways. Since these two pathways share tryptophan as the common nitrogenous substrate, a competition between these pathways is demonstrated. This can result in serotonin deficiency when kynurenine pathway is activated and may contribute to the pathophysiology of developing neurological disease. Furthermore, metabolites of the kynurenine pathway can exert neurotoxic effects because they can cross the blood brain barrier to reach the central nervous system (CNS). Evidence thus far indicates that the contribution of the different pathways of tryptophan metabolism can differ based on the physiological and pathological status. However, there is no clear evidence of whether the kynurenine pathway takes precedence over synthesis of protein (for growth) or serotonin during immune activation. There are also no investigations examining the impact of tryptophan intake during immune activation, for the purposes of this study meaning any activity by the immune system, on the production of neurotoxic metabolites of the kynurenine pathway.

Tryptophan uptake from parenteral nutrition fed to preterm neonates with current amino acid solutions may be about 2-2.5 times the estimated requirement based on data from neonatal piglets. Long-term effects of this excess intake in this vulnerable population are unknown. The potential adverse effects of increased catabolism via the kynurenine pathway during stress on growth and neurodevelopment of hospitalized preterm infants has not been explored. A method to quantify the partitioning of tryptophan between the different pathways will be highly beneficial but has not been established in humans. This will enable studies in parenterally fed neonates to assess whether tryptophan concentrations in current commercial amino acid solutions produce toxic metabolites or serotonin deficiency, which can contribute to neurocognitive deficits seen in this population.
The invention concretely relates to a formula and a preparation method of a Hui Nationality traditional Chinese medicinal Chinese lobelia herb and Andrographis paniculata esophagus cancer treatment granule. The granule is a green high-tech Chinese herbal medicine used for treating the esophagus cancer. The granule is a traditional Chinese medicinal granule prepared through the following steps: mixing of Chinese lobelia herb, Andrographis paniculata, Chinese Sage Herb and other Chinese herbal medicines according to a certain ratio, water adding, decoction, extraction, concentration and granulation. The granule is mainly used for treating the esophagus cancer, and also is used for treating throat cancer, stomach cancer, colorectal cancer and other digestive system cancers. The granule has the characteristics of suitable medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers. The granule fundamentally improves the body functions and prevents and treats cancer cancerization at a low cost in order to recover the health of bodies.
The present invention relates to a composition containing an extract of Camellia sinensis, preferably an extract of a new cultivar of Camellia sinensis (Jangwon No. 3), and more particularly, to a composition containing, as an active ingredient, an extract of a new cultivar of Camellia sinensis having a high content of epigallocatechin 3-O-(3-Omethyl) gallate (EGC G3? Me; 3?-O-Me-EGCG). The composition containing, as an active ingredient, an extract of Camellia sinensis having a high content of epigallocatechin 3-O-(3- O-methyl) gallate according to the present invention has an antioxidant effect due to the elimination and suppression of free radicals, has an anti-aging effect on the skin due to having an excellent ability to inhibit the formation of collagenase, has an anti-inflammatory effect due to inhibiting the expression and secretion of inflammatory factors, such as prostaglandin and IL-8 and the like, in skin cells, has an excellent anticancer effect with respect to cancer cell lines derived from various tissues.  The most suitable drawing: FIG. 4
The aim of the study is to collect data in children with developmental coordination disorder (DCD) aged between 7 and 17 years for analyses of the gait pattern while walking at the Gait Real-time Analysis Interactive Lab (GRAIL). This is a treadmill linked to a virtual environment used to analyse and train gait at the Children's Rehabilitation Centre of Ghent University Hospital. The data from children with DCD will be compared with typically developing children. In this study, only children with DCD will be included and the data resulting from this study will be compared to the data from the previous study in typically developing children (ID: B670201942108).

Children with DCD will be asked to take a motor test (M-ABC-2) as well as walk on the treadmill during a single session of approximately 3 hours. While walking at comfortable walking speed, two short games will be played i.e. dual-tasking. This involves both a cognitive (Stroop Colour-Word Test) and a motor (requires the use of the arms) dual task projected in the virtual environment of the GRAIL. The cognitive and motor task will be performed both while standing still (single tasking: ST) and while walking (dual tasking: DT). Simultaneously, kinetics, kinematics, and EMG data will be collected for 3D gait analysis. Using muscle synergy analysis (based on EMG data), the degree of gait automatization will be analysed. The data from children with DCD will be compared with typically developing children to determine whether a reduced gait automatization can be observed in children with DCD.

Parents will be asked to complete a screening list (CVO/DCD-Q) for motor problems in daily life. This aims as a support to the motor test (M-ABC-2), together providing additional insight into children's motor functioning (in daily life).
An anionic detergent composition comprises an anionic detergent, less than 5% W/V of a metal iodate, based on the total composition, together with at least one other non-active adjuvant. Preferably the concentration of the iodate is 0.1-0.5% W/V. Preferred iodates are NaIO3, KIO3 or NH4IO3.  Preferred anionic detergents are triethanolamine lauryl sulphate, monoethanolamine lauryl sulphate, ammonium lauryl sulphate, or mixtures thereof. The other non-active adjuvants are of the usual type, e.g. dyes, perfumes, cream bases &c. Tests are given comparing the superior anti-microbial power of a metal iodate compared with that of formaldehyde or phenylmercuric borate in the above compositions.
Dynamic MRI acquisition will be performed at two different time points with 10 healthy volunteers under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
Patients randomized to Protect Your Colon™ will be directed to go through the website at least 2 days before their clinic appointment. Those who finish the decision aid will then review their personalized report which details their priorities in selecting a screening test as well as the test that best matches their values. Patients will also be encouraged to bring their personalized report with them to the visit to discuss with their doctor. All intervention participants will also receive a reminder via email one day before their scheduled clinic visit. They will be reminded to go through the Protect Your Colon™ website before the clinic visit and to bring their personalized report with them to the visit.
Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.
Participants with a diagnosis of MDS with genetic confirmation of MECP2 duplication (or triplication) will undergo CSF and blood collection, electrophysiological and clinical assessments, up to Week 104 as a part of prospective study. Each participant's medical and family history data will be collected retrospectively from available medical notes and charts, from birth up to the end of the study (up to 110 weeks). Participants will have an option to participate in an optional sub-study that will capture pre-defined list of activities at home video.